Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Seres Therapeutics (MCRB) Other Non Operating Income (2016 - 2026)

Seres Therapeutics (MCRB) has disclosed Other Non Operating Income for 10 consecutive years, with $2.5 million as the latest value for Q4 2025.

  • Quarterly Other Non Operating Income fell 64.67% to $2.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $16.8 million through Dec 2025, up 224.2% year-over-year, with the annual reading at $16.8 million for FY2025, 218.77% up from the prior year.
  • Other Non Operating Income hit $2.5 million in Q4 2025 for Seres Therapeutics, down from $2.8 million in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $7.1 million in Q1 2025 to a low of -$22.5 million in Q3 2024.
  • Historically, Other Non Operating Income has averaged $82450.0 across 5 years, with a median of $143500.0 in 2022.
  • Biggest five-year swings in Other Non Operating Income: surged 3127.27% in 2023 and later plummeted 2353.95% in 2024.
  • Year by year, Other Non Operating Income stood at -$316000.0 in 2021, then skyrocketed by 92.72% to -$23000.0 in 2022, then surged by 1560.87% to $336000.0 in 2023, then soared by 2006.25% to $7.1 million in 2024, then tumbled by 64.67% to $2.5 million in 2025.
  • Business Quant data shows Other Non Operating Income for MCRB at $2.5 million in Q4 2025, $2.8 million in Q3 2025, and $4.3 million in Q2 2025.